Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-06-30

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the effects of testosterone treatment on erectile function, fatigue, depression, cognitive function, quality of life, urinary incontinence, pain, and damage to neurons in male Multiple Sclerosis patients with low testosterone, using questionnaires, blood samples and a rectal exam in volunteers 55 years and older.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testosterone Treatment for Multiple Sclerosis

NCT00405353

Multiple Sclerosis

COMPLETED PHASE1/PHASE2

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

NCT01585831

Klinefelter Syndrome XXY Syndrome

COMPLETED NA

A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

NCT01419236

Ejaculatory Dysfunction Hypogonadism

COMPLETED PHASE2

Testosterone for Fatigue in Men With MS

NCT03000127

Multiple Sclerosis

WITHDRAWN PHASE2

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

NCT00179517

Seizure Disorder Hypogonadism Erectile Dysfunction

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Volunteers will be treated weekly with Xyosted 75 mg (given subcutaneously) for 3 months during which they will have 3 study visits, 6 weeks apart. The Baseline visit will include providing a blood sample, completing questionnaires, receiving training on the Xyosted auto-injector, and undergoing a rectal exam for participants 55 years and older. Visits 2 and 3 will also include collecting a blood sample and completing questionnaires. At Visit 3, the rectal exam for those age 55 years and older will be repeated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Erectile Dysfunction Testosterone Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single open label

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment open label arm

Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.

Group Type EXPERIMENTAL

XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector

Intervention Type DRUG

Self injection testosterone treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector

Self injection testosterone treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males, age 18 years and older, with a definite diagnosis of multiple sclerosis.
* Low testosterone (\<300 ng/dl) on two successive blood draws before 9:00 am
* Not in an intercurrent relapse.
* Sexually active.
* Have subjective complaints about erectile function and libido.
* Must be willing and able to get labs drawn, complete questionnaires (BDI, MFIS, MSNQ, SDMT, MSQOL, ADAM, AUASS, SHIM, MSHQ, ICIQ, UDI, IIQ, MPQ) and commit to site visits schedule.

Exclusion Criteria

* Males unable to fulfill the above criteria and all female patients.
* Males who have been on sex hormone treatment including androgens, estrogens, or anti-estrogens for hypogonadism or other medical condition during the 12 months prior to study.
* Males who have taken dehydroepiandrosterone (DHEA) during the 3 months prior to study.
* Patients who are taking anticoagulants or have thrombosis, serious cardiac, pulmonary, renal, gastrointestinal, hepatic, immunologic, infectious, neoplastic (with particular focus on patients with known or suspected estrogen or testosterone-dependent tumors), urologic disease especially prostatic hypertrophy/nodules and testicular mass, or insulin-dependent diabetes.
* Patients with an abnormal prostate as evidenced by known history of prostatic disease, symptoms suggestive of prostatic disease or elevated levels of prostatic specific antigen (PSA 4 ng/ml or higher) measured within the last 12 months.
* Patients with history or complaint of testicular mass.
* Patients with hematocrit greater than 50%
* Patients with major psychiatric illness
* Patients with active alcoholism.
* Patients with a history of drug abuse within the past five years.
* Patients with BMI ≥ 35
* Patients with generalized skin disease that may affect absorption of testosterone (e.g. psoriasis) or a known skin intolerance to alcohol.
* Patients with history of pituitary disease.
* Patients with a cholesterol level greater than 300 mg/dl.
* Patients who are receiving or have received experimental therapies in the six months preceding enrollment.
* Patients who have history of positive titers to Human Immunodeficiency Virus (HIV)1 and 2; HTLV1; or Venereal Disease Research Laboratory (VDRL).
* Patients who have clinical evidence of Lyme disease.
* Males who are trying to get their partner pregnant.
* Patients on Finasteride
* Patients who are mentally or emotionally incompetent in the opinion of the examining neurologist or unable to give informed consent, or to understand and comply with the study protocol.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No